Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial (Q37012910)

17 August 2017

1 reference

title

Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial (English)

1 reference

17 August 2017

coronary artery disease

1 reference

4

Maarten L Simoons

1 reference

17 August 2017

Roberto Ferrari

1

1 reference

17 August 2017

Michel E Bertrand

2

1 reference

17 August 2017

Willem J Remme

3

1 reference

17 August 2017

Jaap W Deckers

5

1 reference

17 August 2017

Kim M Fox

6

1 reference

17 August 2017

language of work or name

1 reference

1 November 2007

1 reference

Expert Review of Cardiovascular Therapy

17 August 2017

1 reference

17 August 2017

5

1 reference

17 August 2017

6

1 reference

17 August 2017

1037-1046

1 reference

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

The EUROPA trial: design, baseline demography and status of the substudies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Perindopril: a review of its use in patients with or at risk of developing coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Optimal medical therapy with or without PCI for stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Does preventive PCI work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1037

10.1586/14779072.5.6.1037

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference